New drug aims to outsmart resistant colorectal cancer
NCT ID NCT05426005
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has not responded to standard immunotherapy. The drug is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) to potentially reactivate the immune system against tumors. The main goal is to see how many patients have their tumors shrink or stop growing for at least 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced colorectal cancer whose tumors have stopped responding to current immunotherapies.
- What could go wrong
- This is an early-phase trial with only 28 participants, so results may not apply broadly. The drug may not work or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New blood test could spot colon cancer before it spreads
- Immunotherapy before surgery shows promise for certain colorectal cancers
- New combo shows promise for Tough-to-Treat colorectal cancer
- New blood test could spot colon cancer in young adults before It's too late
- New immunotherapy cocktail targets Hard-to-Treat bowel cancer
- New pill takes on brain tumors and metastases in early trial